DeeperML

Google DeepMind has unveiled TxGemma, an AI designed to improve drug discovery and clinical trial predictions. TxGemma, built upon the Gemma model family, aims to streamline the drug development process and accelerate the creation of new treatments. This announcement comes as Isomorphic Labs, an Alphabet spinout, secured $600 million in funding to further develop its AI drug design engine, which reduces manual labor and speeds up drug development.

Isomorphic Labs' engine uses AI to design small molecules with therapeutic applications, predicting their effectiveness in attaching to disease-causing proteins and mapping properties like solubility. This is powered by models like Google's AlphaFold 3, which can predict the shape of proteins, DNA, and RNA, crucial for drug development. The funding will accelerate Isomorphic Labs' research and development efforts, expand its team, and advance its programs, including those focused on oncology and immunology, toward clinical development.

ImgSrc: res.infoq.com

References :

• AI ? SiliconANGLE: Alphabet spinout Isomorphic Labs raises $600M for its AI drug design engine
• www.infoq.com: Designed to enhance the efficiency of drug discovery and clinical trial predictions.
• www.genengnews.com: DeepMind Spinout Isomorphic Labs Raises $600M Toward AI Drug Design

Classification:

• HashTags: #Google #DeepMind #AIDrugDiscovery
• Company: Google
• Target: Pharmaceutical companies
• Product: Gemma
• Feature: AI Drug Design
• Malware: TXGemma
• Type: AI
• Severity: Informative